{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:00:50Z","timestamp":1782907250828,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK 56338"],"award-info":[{"award-number":["P30 DK 56338"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10620-023-08018-9","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T08:02:04Z","timestamp":1689062524000},"page":"3732-3744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies"],"prefix":"10.1007","volume":"68","author":[{"given":"Sharon","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron P.","family":"Thrift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghida","family":"Akhdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5964-7579","authenticated-orcid":false,"given":"Hashem B.","family":"El-Serag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"8018_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41416-020-0860-4","volume":"123","author":"P Liu","year":"2020","unstructured":"Liu P, McMenamin UC, Johnston BT et al. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer. 2020;123:307\u2013315. https:\/\/doi.org\/10.1038\/s41416-020-0860-4.","journal-title":"Br J Cancer."},{"key":"8018_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0000000000001811","author":"KS Liu","year":"2022","unstructured":"Liu KS, Raza SA, El-Serag HB, Thrift AP. Recent trends in the incidence of gastric cancer in the United States. J Clin Gastroenterol. (Epub ahead of print). 2022. https:\/\/doi.org\/10.1097\/MCG.0000000000001811.","journal-title":"J Clin Gastroenterol. (Epub ahead of print)"},{"key":"8018_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00747-0","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023. https:\/\/doi.org\/10.1038\/s41571-023-00747-0.","journal-title":"Nat Rev Clin Oncol."},{"key":"8018_CR4","doi-asserted-by":"publisher","first-page":"175628481983451","DOI":"10.1177\/1756284819834511","volume":"12","author":"KS Cheung","year":"2019","unstructured":"Cheung KS, Leung WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019;12:1756284819834511. https:\/\/doi.org\/10.1177\/1756284819834511.","journal-title":"Therap Adv Gastroenterol."},{"key":"8018_CR5","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097.","journal-title":"PLoS Med."},{"key":"8018_CR6","unstructured":"Wells GA, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford; 2000."},{"key":"8018_CR7","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ."},{"key":"8018_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","volume":"67","author":"KS Cheung","year":"2018","unstructured":"Cheung KS, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut. 2018;67:28\u201335. https:\/\/doi.org\/10.1136\/gutjnl-2017-314605.","journal-title":"Gut."},{"key":"8018_CR9","doi-asserted-by":"publisher","first-page":"101585","DOI":"10.1016\/j.canep.2019.101585","volume":"62","author":"N Brusselaers","year":"2019","unstructured":"Brusselaers N, Lagergren J, Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. 2019;62:101585. https:\/\/doi.org\/10.1016\/j.canep.2019.101585.","journal-title":"Cancer Epidemiol."},{"key":"8018_CR10","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/gutjnl-2018-316057","volume":"68","author":"YC Peng","year":"2019","unstructured":"Peng YC, Huang LR, Lin CL et al. Association between proton pump inhibitors use and risk of gastric cancer in patients with GERD. Gut. 2019;68:374\u2013376. https:\/\/doi.org\/10.1136\/gutjnl-2018-316057.","journal-title":"Gut."},{"key":"8018_CR11","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/sj.bjc.6605024","volume":"100","author":"AH Poulsen","year":"2009","unstructured":"Poulsen AH, Christensen S, McLaughlin JK et al. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503\u20131507. https:\/\/doi.org\/10.1038\/sj.bjc.6605024.","journal-title":"Br J Cancer."},{"key":"8018_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2165\/00002018-200831080-00004","volume":"31","author":"H Tamim","year":"2008","unstructured":"Tamim H, Duranceau A, Chen LQ, Lelorier J. Association between use of acid-suppressive drugs and risk of gastric cancer. A nested case-control study. Drug Saf. 2008;31:675\u2013684. https:\/\/doi.org\/10.2165\/00002018-200831080-00004.","journal-title":"Drug Saf."},{"key":"8018_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.14309\/ajg.0000000000000591","volume":"115","author":"JK Lee","year":"2020","unstructured":"Lee JK, Merchant SA, Schneider JL et al. Proton pump inhibitor use and risk of gastric, colorectal, liver, and pancreatic cancers in a community-based population. Am J Gastroenterol. 2020;115:706\u2013715. https:\/\/doi.org\/10.14309\/ajg.0000000000000591.","journal-title":"Am J Gastroenterol."},{"key":"8018_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/bjc.2017.84","volume":"116","author":"ECM Wennerstrom","year":"2017","unstructured":"Wennerstrom ECM, Simonsen J, Camargo MC, Rabkin CS. Acid-suppressing therapies and subsite-specific risk of stomach cancer. Br J Cancer. 2017;116:1234\u20131238. https:\/\/doi.org\/10.1038\/bjc.2017.84.","journal-title":"Br J Cancer."},{"key":"8018_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med."},{"key":"8018_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ."},{"key":"8018_CR17","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1136\/gut.2005.086579","volume":"55","author":"LA Garcia Rodriguez","year":"2006","unstructured":"Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55:1538\u20131544. https:\/\/doi.org\/10.1136\/gut.2005.086579.","journal-title":"Gut."},{"key":"8018_CR18","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1158\/1055-9965.EPI-08-0764","volume":"18","author":"L Duan","year":"2009","unstructured":"Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomark Prev. 2009;18:526\u2013533. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0764.","journal-title":"Cancer Epidemiol Biomark Prev."},{"key":"8018_CR19","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1136\/gutjnl-2018-316371","volume":"68","author":"SW Lai","year":"2019","unstructured":"Lai SW, Lai HC, Lin CL, Liao KF. Proton pump inhibitors and risk of gastric cancer in a case-control study. Gut. 2019;68:765\u2013767. https:\/\/doi.org\/10.1136\/gutjnl-2018-316371.","journal-title":"Gut."},{"key":"8018_CR20","doi-asserted-by":"publisher","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","volume":"7","author":"N Brusselaers","year":"2017","unstructured":"Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7:e017739. https:\/\/doi.org\/10.1136\/bmjopen-2017-017739.","journal-title":"BMJ Open."},{"key":"8018_CR21","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1136\/gutjnl-2017-315710","volume":"67","author":"R Niikura","year":"2018","unstructured":"Niikura R, Hayakawa Y, Hirata Y, Yamada A, Fujishiro M, Koike K. Long-term proton pump inhibitor use is a risk factor of gastric cancer after treatment for Helicobacter pylori: a retrospective cohort analysis. Gut. 2018;67:1908\u20131910. https:\/\/doi.org\/10.1136\/gutjnl-2017-315710.","journal-title":"Gut."},{"key":"8018_CR22","doi-asserted-by":"publisher","first-page":"e000719","DOI":"10.1136\/bmjgast-2021-000719","volume":"8","author":"AK Ng","year":"2021","unstructured":"Ng AK, Ng PY, Ip A, Cheung KS, Siu CW. Association between proton pump inhibitors after percutaneous coronary intervention and risk of gastric cancer. BMJ Open Gastroenterol. 2021;8:e000719. https:\/\/doi.org\/10.1136\/bmjgast-2021-000719.","journal-title":"BMJ Open Gastroenterol."},{"key":"8018_CR23","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1136\/gutjnl-2020-323845","volume":"70","author":"SI Seo","year":"2021","unstructured":"Seo SI, Park CH, You SC et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut. 2021;70:2066\u20132075. https:\/\/doi.org\/10.1136\/gutjnl-2020-323845.","journal-title":"Gut."},{"key":"8018_CR24","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/apt.12052","volume":"36","author":"R Fiocca","year":"2012","unstructured":"Fiocca R, Mastracci L, Attwood SE et al. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial. Aliment Pharmacol Ther. 2012;36:959\u2013971. https:\/\/doi.org\/10.1111\/apt.12052.","journal-title":"Aliment Pharmacol Ther."},{"key":"8018_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1046\/j.1365-2036.1996.14156000.x","volume":"10","author":"AL Gough","year":"1996","unstructured":"Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. Aliment Pharmacol Ther. 1996;10:529\u2013539. https:\/\/doi.org\/10.1046\/j.1365-2036.1996.14156000.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"8018_CR26","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/j.1365-2036.2009.04119.x","volume":"30","author":"CW Howden","year":"2009","unstructured":"Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009;30:895\u2013907. https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04119.x.","journal-title":"Aliment Pharmacol Ther."},{"key":"8018_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","volume":"96","author":"DA Johnson","year":"2001","unstructured":"Johnson DA, Benjamin SB, Vakil NB et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol. 2001;96:27\u201334. https:\/\/doi.org\/10.1111\/j.1572-0241.2001.03443.x.","journal-title":"Am J Gastroenterol."},{"key":"8018_CR28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.cgh.2009.05.021","volume":"7","author":"L Lundell","year":"2009","unstructured":"Lundell L, Miettinen P, Myrvold HE et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol. 2009;7:1292\u20131298. https:\/\/doi.org\/10.1016\/j.cgh.2009.05.021.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"8018_CR29","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682-691 e2. https:\/\/doi.org\/10.1053\/j.gastro.2019.05.056.","journal-title":"Gastroenterology."},{"key":"8018_CR30","doi-asserted-by":"publisher","first-page":"175628482110514","DOI":"10.1177\/17562848211051463","volume":"14","author":"D Segna","year":"2021","unstructured":"Segna D, Brusselaers N, Glaus D, Krupka N, Misselwitz B. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therap Adv Gastroenterol. 2021;14:17562848211051464. https:\/\/doi.org\/10.1177\/17562848211051463.","journal-title":"Therap Adv Gastroenterol."},{"key":"8018_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10147-022-02253-2","volume":"28","author":"TR Peng","year":"2023","unstructured":"Peng TR, Wu TW, Li CH. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review and meta-analysis. Int J Clin Oncol. 2023;28:99\u2013109. https:\/\/doi.org\/10.1007\/s10147-022-02253-2.","journal-title":"Int J Clin Oncol."},{"key":"8018_CR32","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/apt.17360","volume":"57","author":"D Piovani","year":"2023","unstructured":"Piovani D, Tsantes AG, Schunemann HJ, Bonovas S. Meta-analysis: use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression. Aliment Pharmacol Ther. 2023;57:653\u2013665. https:\/\/doi.org\/10.1111\/apt.17360.","journal-title":"Aliment Pharmacol Ther."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08018-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08018-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08018-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:09:08Z","timestamp":1692756548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08018-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["8018"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08018-9","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}